1.08
+0.3283(+43.67%)
Currency In USD
| Previous Close | 0.75 |
| Open | 0.75 |
| Day High | 1.37 |
| Day Low | 0.69 |
| 52-Week High | 4.1 |
| 52-Week Low | 0.55 |
| Volume | 66.74M |
| Average Volume | 1.39M |
| Market Cap | 3.84M |
| PE | -0.27 |
| EPS | -3.98 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 2.12 |
| Change | 0.33 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $1.28 as of October 09, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $10.28 as of October 09, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promis
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies con